Myasthenia gravis has specific treatments that may improve nerve-to-muscle signaling and control immune activity
We offer Vitamin D3 as an intramuscular injection (preferred version of supplemental Vitamin D as it is effective at raising the blood levels of vitamin D)
Cycle Length Short courses of about 1020 days, often repeated 12 a year
Use separate syringes - do not mix them
Where they overlap and where they don't Complementary Mechanism Targets Target Origin BPC-157 Gastric juice protein fragment (15 amino acids) TB-500 Thymosin Beta-4 fragment (LKKTETQ region) Target Primary action BPC-157 Local tissue repair signaling TB-500 Systemic cell migration and mobilization Target Angiogenesis BPC-157 VEGF upregulation, NO pathway TB-500 Endothelial migration, VEGF crosstalk Target Cell migration BPC-157 Indirect, via growth factors TB-500 Direct (G-actin sequestering) Target Best-evidence tissue BPC-157 Tendon, gut, gastric mucosa (preclinical) TB-500 Cardiac, corneal, skin (preclinical + early human T4) Target Reported in vivo half-life BPC-157 ~4 hours (animal estimates) TB-500 ~23 days (animal estimates) Half-life figures are pharmacokinetic estimates from animal studies
In the case of BPC-157, this raises a thorny set of questions: In a world of hype and financial conflicts of interest, how informed can patients be